Boston Therapeutics, Inc. Introductory Social Media Launch (www.bostonti.com)

LAWRENCE, Mass., Jan. 16, 2018 -- Boston Therapeutics, Inc.  (OTCQB:BTHE) begun the roll-out of its new Multimedia Internet Platform. The redesigned website offers global insight into the Company’s innovative technology and product offerings, together with a Corporate and investor information section. The new website and platform will allow global access through both fixed and handheld electronic devices and allows users to experience the website in several different languages.

Boston Therapeutics is a global company with significant activities taking place in Hong Kong and throughout the Pacific Rim.  The website was designed to demonstrate the global reach of the Company. Created with user experience in mind, the new website platform has an updated design and improved functionality with easy to access navigation tools. “Our goal is allow potential partners and investors to gain a better understanding of our technology platform as we continue to contribute solutions to unmet medical needs. We are excited about our new platform as it accommodates the growth of our company and our increasing global market presence,” said Carl W Rausch, CEO of Boston Therapeutics Inc.

The newly revamped website, located at the same address www.bostonti.com will be updated on a regular basis and visitors are encouraged to navigate the user-friendly site to find out news related to product launches, business activity, corporate milestones, as well as investor relation and financial information. 

About Boston Therapeutics, Inc.  www.bostonti.com 
Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) is an innovator in design, development and commercialization of compounds, such as BTI-320, to treat diabetes and diabetes related complications. SUGARDOWN is a registered trademark of Boston Therapeutics, Inc.  www.sugardown.com

Forward Looking Statement
This press release includes forward-looking statements. These statements may be identified by words such as "feel," "believes," expects," "estimates," "projects," "intends," "should," "is to be," or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: our limited operations and need to expand in the near future; risks associated with obtaining regulatory approval of our products; the ability to protect our intellectual property; the potential lack of market acceptance of our products; potential competition; our inability to retain key members of our management team; our inability to raise additional capital to fund our operations and business plan; our ability to continue as a going concern; our liquidity and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission ("SEC"), including our annual report on Form 10-K filed with the SEC. Boston Therapeutics expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

Contact: Boston Therapeutics, Inc.
Carl Rausch, CEO 
Phone: 603-935-9799
Email: [email protected] 
www.bostonti.com